Your browser is no longer supported. Please, upgrade your browser.
Settings
PLXP PLx Pharma Inc. daily Stock Chart
PLXP [NASD]
PLx Pharma Inc.
Index- P/E- EPS (ttm)-3.17 Insider Own2.30% Shs Outstand8.92M Perf Week-1.00%
Market Cap44.15M Forward P/E- EPS next Y-1.83 Insider Trans- Shs Float8.54M Perf Month-11.13%
Income-27.80M PEG- EPS next Q-0.44 Inst Own24.50% Short Float1.77% Perf Quarter-14.51%
Sales1.00M P/S44.15 EPS this Y104.70% Inst Trans0.55% Short Ratio14.55 Perf Half Y26.60%
Book/sh-0.51 P/B- EPS next Y-32.80% ROA-122.20% Target Price14.00 Perf Year15.12%
Cash/sh2.72 P/C1.82 EPS next 5Y40.00% ROE-929.70% 52W Range1.00 - 6.44 Perf YTD223.53%
Dividend- P/FCF- EPS past 5Y15.20% ROI-80.60% 52W High-23.13% Beta5.00
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low395.00% ATR0.22
Employees11 Current Ratio4.90 Sales Q/Q200.00% Oper. Margin- RSI (14)42.82 Volatility2.44% 3.96%
OptionableNo Debt/Eq- EPS Q/Q-574.20% Profit Margin- Rel Volume0.16 Prev Close4.95
ShortableYes LT Debt/Eq- EarningsMay 10 BMO Payout- Avg Volume10.42K Price4.95
Recom2.00 SMA20-4.01% SMA50-7.28% SMA20011.11% Volume1,674 Change0.00%
Apr-12-19Resumed Janney Buy
Jan-14-19Downgrade Raymond James Outperform → Mkt Perform
Jun-11-19 12:50PM  Edited Transcript of PLXP earnings conference call or presentation 10-May-19 12:30pm GMT Thomson Reuters StreetEvents
Jun-10-19 04:30PM  PLx Pharma Inc. to Present at JMP Securities Life Sciences Conference GlobeNewswire
May-21-19 11:34AM  Could The PLx Pharma Inc. (NASDAQ:PLXP) Ownership Structure Tell Us Something Useful? Simply Wall St. -5.89%
May-10-19 06:50AM  PLx Pharma Inc. Reports First Quarter 2019 Results GlobeNewswire +5.81%
May-03-19 10:30AM  PLx Pharma (PLXP) Expected to Beat Earnings Estimates: Should You Buy? Zacks
May-02-19 06:50AM  PLx Pharma Inc. to Discuss 2019 First Quarter Financial Results on May 10, 2019 Conference Call GlobeNewswire
Mar-26-19 06:30PM  Edited Transcript of PLXP earnings conference call or presentation 8-Mar-19 1:30pm GMT Thomson Reuters StreetEvents +9.02%
Mar-08-19 06:50AM  PLx Pharma Inc. Reports Fourth Quarter 2018 Results GlobeNewswire
Feb-25-19 04:30PM  PLx Pharma Inc. to Discuss 2018 Fourth Quarter and Full Year Financial Results on March 8, 2019 Conference Call GlobeNewswire
Feb-20-19 04:55PM  PLx Pharma Inc. Announces Completion of $15 Million Convertible Preferred Stock Financing GlobeNewswire
Feb-14-19 11:30AM  PLx Pharma Inc. Announces Adjournment of Special Meeting of Stockholders GlobeNewswire
Jan-17-19 09:55AM  PLx Pharma's Capital Raise More Dilutive Than Expected, Raymond James Says Benzinga
Dec-20-18 07:32PM  PLx Pharma Inc. Announces $15 Million Convertible Preferred Stock Financing GlobeNewswire -24.43%
Dec-18-18 04:30PM  PLx Pharma Inc. to Present at Biotech Showcase 2019 GlobeNewswire -6.92%
Nov-19-18 09:31AM  Edited Transcript of PLXP earnings conference call or presentation 9-Nov-18 1:30pm GMT Thomson Reuters StreetEvents
Nov-09-18 06:50AM  PLx Pharma Inc. Reports Third Quarter 2018 Results GlobeNewswire
Nov-01-18 07:00AM  PLx Pharma Inc. to Discuss 2018 Third Quarter Financial Results on November 9, 2018 Conference Call GlobeNewswire
Oct-01-18 08:57AM  Who Really Owns PLx Pharma Inc (NASDAQ:PLXP)? Simply Wall St.
Sep-10-18 04:30PM  PLx Pharma Inc. to Present at Janney Healthcare Conference on September 18 GlobeNewswire
Aug-10-18 07:00AM  PLx Pharma Inc. Reports Second Quarter 2018 Results GlobeNewswire
Jun-11-18 04:30PM  PLx Pharma Inc. to Present at JMP Securities Life Sciences Conference GlobeNewswire
May-11-18 06:50AM  PLx Pharma Inc. Reports First Quarter 2018 Results GlobeNewswire
Apr-24-18 07:50AM  Blog Exposure - Arcturus Initiates Lawsuit against Former CEO Joseph Payne for Misconduct and Violations of Federal Disclosure ACCESSWIRE -8.14%
Mar-23-18 06:50AM  PLx Pharma Inc. Reports Fourth Quarter and Full Year 2017 Results GlobeNewswire -16.94%
Mar-15-18 04:30PM  PLx Pharma Inc. to Discuss 2017 Fourth Quarter and Full Year Financial Results on March 23, 2018 Conference Call GlobeNewswire
Nov-21-17 07:29PM  Is PLx Pharma Incs (PLXP) Balance Sheet Strong Enough To Weather A Storm? Simply Wall St.
Nov-10-17 06:00AM  PLx Pharma, Inc. to Host Earnings Call ACCESSWIRE
Nov-09-17 06:56PM  PLx Pharma reports 3Q loss Associated Press
PLx Pharma Inc., a late-stage specialty pharmaceutical company, focuses on developing its PLxGuard delivery system to provide various products in the United States. The company's lead product candidates are Vazalore 325 mg and Vazalore 81 mg, which are formulations of aspirin that use the PLxGuard delivery system to reduce acute gastrointestinal (GI) side effects while providing antiplatelet effectiveness for cardiovascular disease prevention. Its product pipeline also includes other oral non-steroidal anti-inflammatory drugs using the PLxGuard delivery system, such as PL1200 Ibuprofen 200 mg, a GI-safer ibuprofen product for pain and inflammation, as well as PL1100 Ibuprofen 400 mg. The company was founded in 2002 and is headquartered in Houston, Texas.